TY - JOUR
T1 - Myocardial contrast echocardiography
T2 - Reliable, safe, and efficacious myocardial perfusion assessment after intravenous injections of a new echocardiographic contrast agent
AU - Meza, Mario
AU - Greener, Yigal
AU - Hunt, Roberta
AU - Perry, Bret
AU - Revall, Susan
AU - Barbee, Wayne
AU - Murgo, Joseph P.
AU - Cheirif, Jorge
N1 - Funding Information:
From the aSection of Cardiology, Department of Internal Medicine, Ochsner Medical Institutions, New Orleans, and the bDepartment of Preclinical Studies of Molecular Biosystems, Inc., San Diego. Received for publication July 10, 1995; accepted Oct. 2, 1995. Supported by a Clinician-Scientist Award (#92004390) of the American Heart Association (Dr. Cheirif) and by an educational grant from Molecular Biosystems, Inc., San Diego, Calif. Reprint requests: Jorge Cheirif B., MD, Section on Cardiology, Ochsner Clinic, 1516 Jefferson Highway, New Orleans, LA 70121. Am Heart J 1996;132:871-81. Copyright © 1996 by Mosby-Year Book, Inc. 0002-8703/96/$5.00 + 0 4/1/72965
PY - 1996
Y1 - 1996
N2 - Reliable and reproducible myocardial opacification after intravenous administration of echocardiographic contrast agents has remained elusive. This study was performed to determine whether a new agent, FS069, a suspension of perfluoropropane-filled albumin microspheres (3.6 μm average microbubble size, concentration 8 x 88/ml), could achieve safe and successful myocardial opacification in open-chest dogs. Seventeen dogs (group 1, n = 7, group 2, n = 10) underwent two-dimensional echocardiography before, during, and after the administration of intravenous FS069. Safety was evaluated by measuring arterial and pulmonary artery pressures, heart rate, blood gases, systolic function, myocardial blood flow, and postmortem analysis of myocardial viability by triphenyl-tetrazolium chloride staining. Efficacy to detect changes in regional myocardial perfusion was assessed by injecting FS069 at baseline, after sequential coronary occlusions and reperfusion, and during intravenous vasodilators with and without coronary occlusions. Results were compared with radiolabeled microspheres. FS069 was found to be safe and effective. In the absence of coronary occlusions, uniform myocardial opacification was observed in all dogs. A perfusion defect was observed in all dogs during coronary occlusions. Background-subtracted peak contrast intensity in the myocardium correctly identified regional myocardial blood flow changes and showed a significant correlation with radiolabeled microspheres (r = 0.65, p = 0.0001).
AB - Reliable and reproducible myocardial opacification after intravenous administration of echocardiographic contrast agents has remained elusive. This study was performed to determine whether a new agent, FS069, a suspension of perfluoropropane-filled albumin microspheres (3.6 μm average microbubble size, concentration 8 x 88/ml), could achieve safe and successful myocardial opacification in open-chest dogs. Seventeen dogs (group 1, n = 7, group 2, n = 10) underwent two-dimensional echocardiography before, during, and after the administration of intravenous FS069. Safety was evaluated by measuring arterial and pulmonary artery pressures, heart rate, blood gases, systolic function, myocardial blood flow, and postmortem analysis of myocardial viability by triphenyl-tetrazolium chloride staining. Efficacy to detect changes in regional myocardial perfusion was assessed by injecting FS069 at baseline, after sequential coronary occlusions and reperfusion, and during intravenous vasodilators with and without coronary occlusions. Results were compared with radiolabeled microspheres. FS069 was found to be safe and effective. In the absence of coronary occlusions, uniform myocardial opacification was observed in all dogs. A perfusion defect was observed in all dogs during coronary occlusions. Background-subtracted peak contrast intensity in the myocardium correctly identified regional myocardial blood flow changes and showed a significant correlation with radiolabeled microspheres (r = 0.65, p = 0.0001).
UR - http://www.scopus.com/inward/record.url?scp=0029956720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029956720&partnerID=8YFLogxK
U2 - 10.1016/S0002-8703(96)90324-5
DO - 10.1016/S0002-8703(96)90324-5
M3 - Article
C2 - 8831379
AN - SCOPUS:0029956720
SN - 0002-8703
VL - 132
SP - 871
EP - 881
JO - American Heart Journal
JF - American Heart Journal
IS - 4
ER -